-
Sector Analysis
NewCell and Gene Therapies in CNS Disorders – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in CNS Disorders Market Report Overview The cell and gene therapies (CGT) sales in central nervous system (CNS) disorders was $1.5 billion in 2023. It will experience significant growth, achieving a CAGR of more than 42% during the forecast period. Gene therapies will dominate the CGT market in CNS disorders because of strong players such as Sarepta Therapeutics and Novartis with marketed products Elevidys and Zolgensma, respectively. Cell and Gene Therapies in CNS Disorders Market Outlook...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amifampridine Phosphate LA in Lambert–Eaton Myasthenic Syndrome (LEMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amifampridine Phosphate LA in Lambert–Eaton Myasthenic Syndrome (LEMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Amifampridine Phosphate LA in Lambert–Eaton Myasthenic Syndrome (LEMS)...
-
Product Insights
Myasthenia Gravis – Drugs In Development, 2023
Global Markets Direct’s, ‘Myasthenia Gravis - Drugs In Development, 2023’, provides an overview of the Myasthenia Gravis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myasthenia Gravis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Sector Analysis
Rheumatoid Arthritis (RA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Reasons to buy the ‘Rheumatoid Arthritis (RA)’ marketed and pipeline drugs assessment report: Get a comprehensive overview of the rheumatoid arthritis market including disease epidemiology, treatment guidelines, clinical trials, deals, and an assessment of marketed and pipeline drugs. Get an insight into MoA, RoA, and molecule types for the leading marketed and pipeline drugs in RA. Assess the pricing and reimbursement of rheumatoid arthritis marketed and pipeline drugs. Get a detailed assessment of the clinical trials taking place within the...
-
Sector Analysis
Anal Cancer (AC) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Anal Cancer Marketed and Pipeline Drugs Report Overview Anal cancer develops in the cells and tissue of the skin lining on either the inside or outside of the anus. The development of anal cancer is directly linked to a complex inflammatory process secondary to infections such as (HPV) types 16 and 18. The progression of this inflammatory process heralds the development of anal intraepithelial neoplasia (AIN), or squamous cell carcinoma (SCC) in situ (Bowen disease), which is a pre-malignant condition....
-
Sector Analysis
Menopausal Disorders (MD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Menopausal Disorders (MD) Marketed and Pipeline Drugs Report Overview Menopausal disorders are a permanent cessation of menstruation resulting in the loss of ovarian follicle development. In 2023, the highest number of prevalent cases of menopausal disorders were registered in India and China. Treatment guidelines for MD are well-established globally and at the country level and are updated periodically. For instance, in 2023, the US and China updated guidelines. In the US, guidelines were provided by the North American Menopause Society...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – E-602 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - E-602 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.E-602 in Non-Small Cell Lung Cancer Drug Details:E-602 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amifampridine Phosphate La in Lambert–Eaton Myasthenic Syndrome (LEMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Amifampridine Phosphate La in Lambert–Eaton Myasthenic Syndrome (LEMS) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Amifampridine Phosphate La in Lambert–Eaton Myasthenic Syndrome (LEMS)Drug Details:...
-
Company Insights
Innovation and Patenting activity of Catalyst Pharmaceuticals Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Catalyst Pharmaceuticals Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...